Benitec Biopharma Price to Free Cash Flow Ratio 2014-2022 | BNTC
Historical price to free cash flow ratio values for Benitec Biopharma (BNTC) since 2014.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Benitec Biopharma Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2022-08-08 |
0.78 |
|
0.00 |
| 2022-03-31 |
2.34 |
$-542.31 |
0.00 |
| 2021-12-31 |
2.62 |
$-517.77 |
0.00 |
| 2021-09-30 |
3.57 |
$-290.00 |
0.00 |
| 2021-06-30 |
4.25 |
$-607.82 |
0.00 |
| 2021-03-31 |
5.17 |
$-995.84 |
0.00 |
| 2020-12-31 |
3.00 |
$-1,649.68 |
0.00 |
| 2020-09-30 |
6.28 |
$-1,918.05 |
0.00 |
| 2020-06-30 |
7.91 |
$-1,499.45 |
0.00 |
| 2020-03-31 |
3.93 |
$-845.62 |
0.00 |
| 2019-09-30 |
7.11 |
$-137.50 |
0.00 |
| 2017-09-30 |
21.70 |
$-10.69 |
0.00 |
| 2016-09-30 |
14.00 |
$-7.13 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
